Osteomark gets boost from Merck's Fosamax:
This article was originally published in Clinica
Executive Summary
US approval on October 2nd of Merck & Co's nonhormonal treatment for osteoporosis in post-menopausal women has been welcomed by Ostex which produces Osteomark, the first commercially available test to measure bone resorption. Trial data show that the Ostex test has potential use in monitoring patients' response to Fosamax therapy, says Dr B Gertz of Merck Research Laboratories and a member of the Ostex scientific advisory board.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.